Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Recruiting now · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Congestive Heart Failure, Heart Failure, Systolic, Heart Failure, HFrEF - Heart Failure With Reduced Ejection Fraction
In brief
It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis, resulting in improved cardiac contractile function and energetics which will, in turn, translate to improved clinical outcomes. Additionally, it is hypothesized that correcting SERCA2a dysfunction will also improve coronary blood flow through correction of the impaired endothelium-dependent nitric oxide-mediated vasodilatation observed in heart failure.
Key facts
- Study ID
- NCT04703842
- Run by
- Sardocor Corp.
- People needed
- 57
- Starts
- 2021-09-23
- Expected to finish
- 2028-12-01
- Last updated by the study team
- 2024-03-26
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- San Diego Cardiac Center — San Diego, California, United States (enrolling)
- University of California, San Francisco — San Francisco, California, United States (enrolling)
- Washington University in Saint Louis — St Louis, Missouri, United States (enrolling)
- University of Texas Southwestern Medical Center — Dallas, Texas, United States (enrolling)
- University of Washington Medicine — Seattle, Washington, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.